Please assess the completion status of the following clinical trial:

Trial Title: A Study Based on Japanese Medical Records That Looks at Bleeding Events in People With Atrial Fibrillation and Coronary Artery Disease Who Start Taking Either Dabigatran, Rivaroxaban, or Warfarin

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~-≥18 years of age~* Has one year of look-back period prior to the index date (defined as the first date of prescription for dabigatran, rivaroxaban, or warfarin during the study period)~* New users of warfarin, dabigatran, and rivaroxaban, defined as patients without historic use of any oral anticoagulants during the look-back period~* Has at least 1 diagnosis of NVAF during the look-back period prior to or on the index date~* Has at least 1 diagnosis of CAD during the look-back period prior to or on the index date~Exclusion Criteria:~* Diagnosed with end-stage renal disease, or undergo hemodialysis, or experience pregnancy during the study period~* Initiate warfarin, dabigatran, rivaroxaban due to valvular Atrial Fibrillation (AF), AF associated with mechanical valve malfunction or mechanical complication of heart valve prosthesis, or rheumatic AF~* Underwent joint replacement procedures or diagnosed with venous thromboembolism during the look-back period prior to or on the index date~* Prescribed with more than 1 oral anticoagulation (OAC) on the index date~* Prescribed with more than 2 anti-platelet drugs per prescription (triple or quadruple anti-platelet use), or prescribed with any anti-platelet injection~* Patients with missing or ambiguous age or sex information

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Warfarin (Type: None): All eligible Japanese on-valvular atrial fibrillation (NVAF) patients with concomitant Coronary Artery Disease (CAD), who were prescribed with warfarin. From existing data from the Japan Medical Data Vision Co. Ltd. (MDV) database, which covered all insurance types and a large population size.~The study period started on April 18th, 2011 (start of data collection) to December 31st, 2020 (end of data collection).
- Dabigatran (Type: None): All eligible Japanese on-valvular atrial fibrillation (NVAF) patients with concomitant Coronary Artery Disease (CAD), who were prescribed with dabigatran. From existing data from the Japan Medical Data Vision Co. Ltd. (MDV) database, which covered all insurance types and a large population size.~The study period started on April 18th, 2011 (start of data collection) to December 31st, 2020 (end of data collection).
- Rivaroxaban (Type: None): All eligible Japanese on-valvular atrial fibrillation (NVAF) patients with concomitant Coronary Artery Disease (CAD), who were prescribed with rivaroxaban. From existing data from the Japan Medical Data Vision Co. Ltd. (MDV) database, which covered all insurance types and a large population size.~The study period started on April 18th, 2011 (start of data collection) to December 31st, 2020 (end of data collection).

Based on this trial design, predict the completion outcome and termination type (if applicable).